Updated Molecular Testing Guideline for the Selection of Lung Cancer Patients for Treatment With Targeted Tyrosine Kinase Inhibitors-Reference-Cited by-同舟云学术

Updated Molecular Testing Guideline for the Selection of Lung Cancer Patients for Treatment With Targeted Tyrosine Kinase Inhibitors

Published:2018-03 Issue:3 Volume:13 Page:323-358
ISSN:1556-0864
Container-title:Journal of Thoracic Oncology
language:en
Short-container-title:Journal of Thoracic Oncology

Author:

Lindeman Neal I.,Cagle Philip T.,Aisner Dara L.,Arcila Maria E.,Beasley Mary Beth,Bernicker Eric H.,Colasacco Carol,Dacic Sanja,Hirsch Fred R.,Kerr Keith,Kwiatkowski David J.,Ladanyi Marc,Nowak Jan A.,Sholl Lynette,Temple-Smolkin Robyn,Solomon Benjamin,Souter Lesley H.,Thunnissen Erik,Tsao Ming S.,Ventura Christina B.,Wynes Murry W.,Yatabe Yasushi

Publisher

Elsevier BV

Subject

Pulmonary and Respiratory Medicine,Oncology

Reference263 articles.

1. Molecular Testing Guideline for Selection of Lung Cancer Patients for EGFR and ALK Tyrosine Kinase Inhibitors: Guideline from the College of American Pathologists, International Association for the Study of Lung Cancer, and Association for Molecular Pathology

2. Molecular Testing Guideline for Selection of Lung Cancer Patients for EGFR and ALK Tyrosine Kinase Inhibitors: Guideline from the College of American Pathologists, International Association for the Study of Lung Cancer, and Association for Molecular Pathology

3. Molecular Testing Guideline for Selection of Lung Cancer Patients for EGFR and ALK Tyrosine Kinase Inhibitors

4. Molecular Testing for Selection of Patients With Lung Cancer for Epidermal Growth Factor Receptor and Anaplastic Lymphoma Kinase Tyrosine Kinase Inhibitors: American Society of Clinical Oncology Endorsement of the College of American Pathologists/International Association for the Study of Lung Cancer/Association for Molecular Pathology Guideline

5. Ettinger DS, Wood DE, Aisner DL, et al. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines): non-small cell lung cancer. Version 6.2017. National Comprehensive Cancer Network, Inc. https://www.nccn.org. Accessed June 12, 2017.

Cited by 374 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. ROS1-rearranged non-small cell lung cancer: Understanding biology and optimizing management in the era of new approvals;Current Problems in Cancer;2024-12

2. Pulmonary Cytopathology;Surgical Pathology Clinics;2024-09

3. Minimally Invasive, Maximally Effective;Surgical Pathology Clinics;2024-09

4. Clinical Validity and Utility of Circulating Tumor DNA (ctDNA) Testing in Advanced Non-small Cell Lung Cancer (aNSCLC): A Systematic Literature Review and Meta-analysis;Molecular Diagnosis & Therapy;2024-08-02

5. Biomarker Testing for Guiding Precision Medicine for Patients with Non-Small Cell Lung Cancer;CHEST;2024-08